Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Matrixx settles Zicam suits

This article was originally published in The Tan Sheet

Executive Summary

Matrixx has reached a settlement agreement intended to end 90% of the product liability litigation related to the firm's ZicamCold Remedy Nasal Gel, the company announces Jan. 19. The suits, filed in April 2004 in Arizona state court, involve approximately 340 plaintiffs who allege that use of the cold product caused them to lose their sense of smell. As a result of the settlement, the plaintiffs will dismiss their case with prejudice in return for an undisclosed sum of money. The individual amounts will be determined by medical protocol, Matrixx adds. The firm expects to pay a total of $12 mil. to fund the program; in order to go ahead with the settlement, 95% of the plaintiffs must accept the terms within two months, according to the firm. The company will "continue to fight" related litigation in Alabama and Colorado, a company spokesperson said (1"The Tan Sheet" Nov. 13, 2004, p. 13)...

You may also be interested in...

Zinc Gluconate Sprays Challenged In Lawsuits; Matrixx Defends Zicam Safety

The safety of zinc gluconate sprays has been called into question by a recent spate of lawsuits alleging that the products cause users to lose their sense of smell

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts